TARA PROTARA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, PROTARA THERAPEUTICS INC reported revenue of n/a, net income of −$21.7M and diluted EPS of −$0.36; for the fiscal year ended December 2025 revenue was n/a.
TARA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$64.5M, net income −$57.4M (margin n/a), EPS −$1.34
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$49.2M, net income −$44.6M (margin n/a), EPS −$2.17
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$43.6M, net income −$40.4M (margin n/a), EPS −$3.57
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$67.1M, net income −$66.0M (margin n/a), EPS −$5.86
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$47.5M, net income −$47.3M (margin n/a), EPS −$4.21
TARA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$21.7M, EPS −$0.36
- Quarter ended Mar 31, 2026: revenue n/a, net income −$17.8M, EPS −$0.31
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$17.3M, EPS −$0.39
- Quarter ended Sep 30, 2025: revenue n/a, net income −$13.3M, EPS −$0.31
- Quarter ended Jun 30, 2025: revenue n/a, net income −$15.0M, EPS −$0.35
- Quarter ended Mar 31, 2025: revenue n/a, net income −$11.9M, EPS −$0.29
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$12.8M, EPS −$0.25
- Quarter ended Sep 30, 2024: revenue n/a, net income −$11.2M, EPS −$0.50
- Quarter ended Jun 30, 2024: revenue n/a, net income −$9.51M, EPS −$0.45
- Quarter ended Mar 31, 2024: revenue n/a, net income −$11.1M, EPS −$0.97
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$10.2M, EPS −$0.90
- Quarter ended Sep 30, 2023: revenue n/a, net income −$9.86M, EPS −$0.87
- Quarter ended Jun 30, 2023: revenue n/a, net income −$11.3M, EPS −$1.00
- Quarter ended Mar 31, 2023: revenue n/a, net income −$9.05M, EPS −$0.80
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$39.0M, EPS −$3.46
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.69M, EPS −$0.68
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.54M, EPS −$0.76
- Quarter ended Mar 31, 2022: revenue n/a, net income −$10.8M, EPS −$0.96
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$10.2M, EPS −$0.91
- Quarter ended Sep 30, 2021: revenue n/a, net income −$10.8M, EPS −$0.96
TARA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$56.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$35.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$37.6M, share buybacks $91.0K
- Fiscal year ended Dec 2022: operating cash flow −$26.5M, share buybacks $90.0K
- Fiscal year ended Dec 2021: operating cash flow −$34.5M, share buybacks $228K
TARA balance sheet
- Jun 30, 2026: cash $17.1M, total assets $176M, total liabilities $14.8M, shareholders' equity $161M
- Mar 31, 2026: cash $14.7M, total assets $192M, total liabilities $10.7M, shareholders' equity $181M
- Dec 31, 2025: cash $49.7M, total assets $209M, total liabilities $13.1M, shareholders' equity $196M
- Sep 30, 2025: cash $12.6M, total assets $145M, total liabilities $12.3M, shareholders' equity $132M
- Jun 30, 2025: cash $31.5M, total assets $157M, total liabilities $12.5M, shareholders' equity $144M
- Mar 31, 2025: cash $91.5M, total assets $169M, total liabilities $10.1M, shareholders' equity $158M
- Dec 31, 2024: cash $163M, total assets $181M, total liabilities $14.3M, shareholders' equity $167M
- Sep 30, 2024: cash $51.8M, total assets $94.1M, total liabilities $12.3M, shareholders' equity $81.8M
Is TARA profitable?
No. PROTARA THERAPEUTICS INC lost $70.0M over the last four quarters.
What is TARA's EPS?
Diluted earnings per share over the last four quarters were −$1.37; −$0.36 in the latest quarter.